Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02504216 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 6,564
- Enrollment target
NCT02504216 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 6,564 participants.
The verdict
NCT02504216, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 6,564 participants
- Enrollment target
Study Summary
The purpose of study was to test whether rivaroxaban added to standard of care treatment, when compared to placebo, had the potential to reduce the incidence of the clinical events related to the clots and complications of the heart and brain (CV death, MI, or stroke) or the legs (acute limb ischemia or major amputation) in patients who had undergone recent procedure(s) to improve the blood flow of their legs.
Interventions
- DRUG Rivaroxaban (Xarelto, BAY59-7939)
- DRUG Rivaroxaban-Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,564 participants |
| Start Date | 2015-08-18 |
| Est. Completion | 2020-01-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02504216
The ClinicalTrials.gov registry entry for NCT02504216 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 6,564 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rivaroxaban (Xarelto, BAY59-7939) is the first listed.
NCT02504216 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02504216 about?
NCT02504216 is a clinical study titled "Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities". The purpose of study was to test whether rivaroxaban added to standard of care treatment, when compared to placebo, had the potential to reduce the incidence of the clinical events related to the clots and complications of the heart and brain (CV death, MI, or stroke) or the legs (acute limb ischemi...
What is the current status of trial NCT02504216?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 6,564 participants. The study started on 2015-08-18. Estimated completion is 2020-01-09.
What interventions are being tested in trial NCT02504216?
The interventions under investigation include: Rivaroxaban (Xarelto, BAY59-7939) (DRUG), Rivaroxaban-Placebo (DRUG).
Who is sponsoring clinical trial NCT02504216?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.